Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

What Was Tested

Researchers studied Angiotensin II in this controlled clinical trial publication.

The aim of this study was to investigate the relationships between plasma concentrations of losartan, an orally active angiotensin II inhibitor, its active metabolite EXP3174, and angiotensin II blockade.

Why It Was Studied

EXP3174 reached higher plasma concentrations and was eliminated more slowly than its parent compound; its levels paralleled the profile of angiotensin II blockade closer than losartan.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a placebo-controlled, crossover and parallel-group study.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Angiotensin II blockade was assessed by the blood pressure response to exogenous angiotensin II before and after losartan administration.

What Was Measured

EXP3174 reached higher plasma concentrations and was eliminated more slowly than its parent compound; its levels paralleled the profile of angiotensin II blockade closer than losartan.

The subject headings attached to it are Aldosterone, Analysis of Variance, Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Biotransformation and Biphenyl Compounds.

What This Means in Plain Language

The paper is a placebo-controlled, crossover and parallel-group study of Angiotensin II.

The publication is from 1992 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.